Report Categories
View AllRecent Articles
View All
How Ibotta IBTA thinks about risk management Ibotta posts 292 negative EPS miss well below estimates
ESPR Esperion Therapeutics reports Q4 2025 EPS miss shares post small gains even as earnings lag analyst estimates
BAM Brookfield AM posts 6 percent Q4 2025 EPS beat driving a 428 percent share gain in todays trading
What circuit breakers Kewaunee KEQU Investors Pile In 20260429